Kornimate/medical-research-clean huggingface dataset:
inhibitors of angiotensin ii in proteinuric mesangioproliferative glomerulonephritis

Conditions: IGA Glomerulonephritis

Summary: this study evaluates prospectively the effects of an anti-angiotensin ii regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

after signing informed consent, enrolled patients started treatment with acei. we decided to prescribe to all patients the same drug (ramipril) at the same dosage (5 mg/day). all patients were examined every 2 months during the first year of follow-up and every 6 months thereafter. at each visit, they underwent a complete physical examination. if the target blood pressure of \<140/90 mmhg was not achieved with ramipril monotherapy, addition of other antihypertensive drug(s) was allowed. patients complaining adverse side effects attributed to ramipril were switched to losartan (50 mg/day). the patients were also prescribed a normal protein (1 gram/kg/day) and moderately salt-restricted (6-8 grams/day) diet throughout the study.

Eligibility criteria:
inclusion criteria: * proteinuria ≥ 1 g and \< 3 g/24 hours stable during the 3 months of run-in * microscopic hematuria (with at least 10 red blood cells per high-power field), without other signs or symptoms of systemic diseases stable during the 3 months of run-in * no-evidence of renal failure or other relevant diseases * biopsy diagnosis of i-ii stage iga- or pauciimmune-mspgn exclusion criteria: * estimated glomerular filtration rate (egfr) \<80 ml/min/1.73m2 * previous immunosuppressive treatment * blood pressure (bp) \>150/90 mmhg
genetic mutation in recurrent cervical cancer

Conditions: Recurrent Cervical Cancer; Nucleotide Variant; Copy Number Variation; Insertion-deletion Variation; Genomic Structural Variation; Total Mutation Burden; Microsatellite Instability; PD-1; PD-L1

Summary: little is known about the characteristics of genetic mutation in recurrent cervical cancer. this study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes. the mutation characteristics are to be revealed in single nucleotide variants, copy number variations, insertion-deletion variations, and genomic structural variations. the total mutation burden (tmb) will be calculated. the status of microsatellite instability, expression of pd-1 and pd-l1 antibodies are also tested. these findings will be studies in association with the patients' prognosis and sensitivity to platinum-based chemotherapy and immunotherapy.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma * with available materials for analysis * with detailed clinicopathological information * given consent to participate the trial exclusion criteria: * not meeting all of the inclusion criteria
frequency of hypodontia after chemotherapy in childhood cancer survivors study

Conditions: Hypodontia

Summary: this study aims to provide information on the frequency of hypodontia in children cancer survivors receiving chemotherapy before 4 years of age.patients who met the eligibility criteria will be given a structured questionnaire to fill followed by a radiographic examination (dental panorama) for confirmation and standardization of the results.


Eligibility criteria:
inclusion criteria: * aged 4 years or less when they first started their antineoplastic chemotherapy * both genders * able to cooperate exclusion criteria: * children with known family history of hypodontia * children with any associated developmental anomalies (eg, ectodermal dysplasia, cleft lip or palate and down syndrome) * children who received radiotherapy * children with previous loss of teeth due to trauma, caries, periodontal disease or extraction 5- children who received bone marrow transplantation 6-parents/patients unwilling to give informed consent
intraperitoneal infusion of epcam car-t cell in advanced gastric cancer with peritoneal metastasis (wch-gc-cart)

Conditions: Neoplasm, Stomach; Metastases, Neoplasm; Neoplasm Seeding

Summary: to investigate the safety and efficacy of intraperitoneal infusion of epcam car-t cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.

chimeric antigen receptor modified t (car-t) cells have the capability in targeting and recognizing tumor antigen, and can specifically recognize, bind and kill tumor cells with positive antigen. through local drug delivery, car-t cells have successfully achieved remarkable effect to treat solid tumors. gastric cancer is one of the most frequent malignant tumors with high mortality, especially in china. peritoneal metastasis is one of the common routes of metastasis. once peritoneal metastasis occurred, patients should be categorized as clinical pathological stage iv with extremely poor prognosis, and the effect of routine treatments would be unsatisfactory. epithelial cell adhesion molecule (epcam) is highly expressed in gastric cancer cells and closely associated with the poor prognosis of patients. in our previous pre-clinical research researches, the investigators have obtained car-t cells targeting epcam (epcam car-t), and finished the preparations of cells which could be used in clinical practice. based on our previous works, the investigators aim to investigate the safety and efficacy of peritoneal infusion of epcam car-t cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial. the results of this clinical trial are expected to provide the new treatment strategy for gastric cancer patients with peritoneal metastasis.

Eligibility criteria:
inclusion criteria: 1. patients with epcam positive gastric cancer who have peritoneal metastasis at first visit; patients with highly suspected or previous proven peritoneal metastasis by biopsy, ct, digital rectal examination, etc. who failed to the routine therapies like chemotherapy; 2. age between 18 and 75; 3. estimated survival time is longer than 3 months; 4. eastern cooperative oncology group (ecog）scores 0-2; 5. hemoglobin≥90g/l, anc≥1.5×109/l, plt≥80×109/l; 6. negative pregnancy test for child-bearing period; both male and female patients should agree to apply effective contraceptive methods in the period of treatment and one year after treatment; 7. both patients and families totally understand the objectives and risks of the treatments and sign the informed consent. exclusion criteria: 1. comorbidity with other diseases treated by immunosuppressive drugs or steroids therapy systematically; 2. uncontrolled active infection; 3. hiv positive; 4. active hepatic b or c virus infection, active tuberculosis; 5. pregnant or lactation female; 6. disagree to apply effective contraceptive methods in the period of treatment and one year after treatment; 7. positive cytology examination alone.

Keywords: epithelial cell adhesion molecule chimeric antigen receptor-modified t cell gastric carcinoma peritoneal metastasis
effect of a cooling sensation flavor on the swallow response in post-stroke patients with oropharyngeal dysphagia

Conditions: Oropharyngeal Dysphagia; Stroke; Swallowing Disorder

Summary: current oropharyngeal dysphagia (od) treatment in older patients is based on compensatory strategies (fluid thickening and texture modified diets) that improve swallow safety but do not improve the swallowing function. one of these strategies is thickening products, which are used to reduce pharyngeal bolus velocity by increasing viscosity of fluids. there are several studies demonstrating the therapeutic effect of thickeners in reducing the prevalence of penetrations and aspirations, and their use has been correlated with reduced prevalence of respiratory infections, aspiration pneumonia and hospital readmissions. in recent years, new neurorehabilitation treatment strategies for od have been developed such as peripheral (electrical or chemical stimulation) or central stimulation (transcranial direct current stimulation or repetitive transcranial magnetic stimulation). the investigators suggest that new generation treatments for od have to combine thickened fluids and about peripheral stimulation using transient receptor potential (trp) channels agonists. the aim of this study is to evaluate the therapeutic effect of a cooling sensation (cs) flavor in a pre-thickened oral nutritional supplement (ons) drink on the biomechanical mechanism of the swallow response in chronic post-stroke patients with od. the investigators designed a randomized, crossover, interventional and open-label clinical study. the study includes 2 groups: 1) n=25: 1st visit: stimulation with control, 2nd visit: stimulation with cs; and 2) n=25: 1st visit: stimulation with cs, 2nd visit: stimulation with control. each patient will attend a total of 2 visits, with a washing period of at least 7 days between visits. the procedures to be performed during each visit are: clinical assessment of swallowing with v-vst, spontaneous swallowing frequency measurement using electromyography, and collection of a sample of saliva using a salivette®.


Eligibility criteria:
inclusion criteria: * ≥18 years * patients with chronic od as a consequence of stroke (more than 3 month since stroke diagnostic) * patients with impaired safety and/or efficacy of swallow (v-vst) * patients that can swallow safely the investigation and control product according to the viscosity of the product and the results of the v-vst * patients able to follow the protocol and give informed consent exclusion criteria: * pregnancy * life expectancy \<3 months or palliative care * od diagnosis prior to stroke * dementia (gds 4 or higher) * allergy to the investigation and/or control product or to any of its components * participation in another interventional study in the month prior to inclusion * current users of a pre-thickened ons drink with cooling sensation flavor
safety and efficacy study of bimatoprost to treat hypotrichosis of the eyelashes after application to the eyelid margin

Conditions: Hypotrichosis

Summary: this one-year study evaluates the long-term safety and effectiveness of bimatoprost solution application to the eyelid margin (where the eyelashes meet the skin) to treat hypotrichosis of the eyelashes (inadequate or not enough eyelashes). there will be two different types of subjects participating in the study 1)those with inadequate eyelashes due to natural causes or 2) those with inadequate eyelashes following a complete course of chemotherapy treatment. there will be two treatment periods of six months each. subjects will receive either the study medication or vehicle in either of the two treatment periods.


Eligibility criteria:
inclusion criteria: * subjects who have inadequate eyelashes due to natural causes and are not satisfied with their eyelash appearance. * for the post-chemotherapy population: subjects who have inadequate eyelashes following a complete course of chemotherapy treatment and are not satisfied with their eyelash appearance, are considered free of cancer and are well enough to complete the study. exclusion criteria: * subjects with unequal right and left eyelashes, any eye disease or abnormality, eye surgery, permanent eyeliner, eyelash implants, eyelash extension application. * any use of over the counter or prescription use eyelash growth products. * subjects requiring eye drop medications for glaucoma. * females who are pregnant, nursing or planning a pregnancy during the study or who are of childbearing potential and not using a reliable method of contraception.

Keywords: eyelashes
vitamin d loading dose in advanced lung cancer

Conditions: Lung Cancer

Summary: hypovitaminosis d is highly prevalent in people with lung cancer, and may have adverse clinical consequences. the long and variable pharmacokinetic half-life of vitamin d makes prompt vitamin d replacement problematic. this is an open, one-armed therapeutic intervention using a loading dose of vitamin d that will be predicted to increase plasma 25-hydroxyvitamin d concentrations of every patient well into the normal range (\> 100 nmol/l) within 2 or 3 weeks and monitored after 2 and 3 weeks of loading and maintenance dose. preliminary data will also be obtained to identify potentially clinical important outcome benefits for future investigation. the outcomes are 1. plasma 25ohd concentration 2. vitamin d binding protein and other plasma concentrations 3. mood and symptom


Eligibility criteria:
inclusion criteria: 1. any patient with advanced lung cancer whether or not receiving specific anti-cancer therapy 2. mentally competent (but need not be fluent in french or english if capable neutral translator available) 3. self report of reduced food intake and/or involuntary weight loss of any extent at time of enrollment: does not have to be documented exclusion criteria: 1. current diagnosis of primary hyperparathyroidism 2. nephrocalcinosis 3. current or suspected active tuberculosis, histoplasmosis, sarcoidosis, or other granulomatous disease 4. current using a vitamin d supplement providing \> 1000 iu/day 5. current prescribed calcitriol in any dose 6. history of extensive sunlight exposure (\> 30 min summer sunlight exposure per day for more than 5 days per week) in previous 3 months 7. expected to die within next 2 months 8. pregnancy

Keywords: lung cancer vitamin d pharmacokinetics
effect of the hockey slideboard training combined with blood flow restriction (bfr) in the rehabilitation following anterior cruciate ligament surgical reconstruction (acl-r)

Conditions: Anterior Cruciate Ligament Rupture; Rehabilitation After ACL Reconstruction

Summary: acl injuries represent a major health and economic burden. the overall incidence of acl injuries has increased and is likely to continue to increase, in part due to increased sports participation. in the acute post-surgical phase there is a period of physiologic recovery from the surgical injury and subsequent relative muscle disuse that is associated with atrophy loss of strength and anterior knee pain. therefore, improvement of muscle function is a priority in the rehabilitation and reathletization process. to achieve significant muscle hypertrophy as well as a possible subsequent increase in strength, it is widely accepted that resistance exercises with relevant load (\~70% of the one repetition maximum - 1rm) are necessary; however, in patients undergoing anterior cruciate ligament reconstruction (acl-r), exercises with high loads are considered unsafe in the early stages and could increase the risk of re-injury. bfr training is an established muscle training and rehabilitation technique in which the blood supply to and from the muscles involved in the exercise is restricted using an external device. although the physiological mechanisms related to this intervention are not yet well understood, it is thought that in bfr training, despite the low level of mechanical tension, the main driver of myocellular hypertrophy could be metabolic stress that is realized by local accumulation of metabolites. thus, it seems that hypertrophic adaptations can be induced with much lower exercise intensities using bfr. in fact, when combined with low-load resistance training (e.g., 20% 1rm), training with bfr has shown positive results in increasing muscle volume and strength after acl-r in complete safety comparable to standard training without bfr. it has also already been demonstrated how incorporating the use of the hockey slideboard into the rehabilitation procedure following acl-r gives benefits in terms of strength recovery of the extensor muscles of the operated limb with the same safety profiles as standard rehabilitation.


Eligibility criteria:
inclusion criteria: * having undergone acl-r following a unilateral rupture, with reconstructive surgical technique by bone-patellar tendon-bone autograft (bptb) or semitendinosus-gracilis autograft (stg) * acl-r including associated meniscal lesions treated with selective meniscectomy and/or non-complex meniscal suture exclusion criteria: * not having undergone acl-r following a unilateral rupture, with reconstructive surgical technique by bone-patellar tendon-bone autograft (bptb) or semitendinosus-gracilis autograft (stg)
a single-center phase ii study to investigate the immune maintenance therapy pattern in patients with locally advanced head and neck squamous cell carcinoma who have achieved mpr after neoadjuvant immunotherapy combined with chemotherapy

Conditions: Head and Neck Cancer

Summary: head and neck cancer is the malignant tumor with the highest morbidity and mortality, of which 60% present with locally advanced disease at initial diagnosis, and the 5-year survival rate of standard treatment is less than 30%. standard of care (soc) including adjuvant and neoadjuvant therapy can provides only about 5-10% clinical benefit. according to the available data on the application of immunotherapy as adjuvant therapy in operable patients, adjuvant immunotherapy is safe and feasible, with a significant trend of benefit. based on the above positive and meaningful clinical needs and scientific basis, it is very necessary to carry out clinical trials of adjuvant immunotherapy. the primary objective of this study is to evaluate the efficacy and safety of immune maintenance therapy in patients with locally advanced head and neck squamous cell carcinoma who achieve mpr after neoadjuvant immunotherapy combined with chemotherapy.


Eligibility criteria:
inclusion criteria: * able to understand and willing to give an informed consent for the study. * males or females aged 18 to 80 years. * have an eastern co-operative oncology group (ecog) performance status less than equal to 1. * pathologically (histologically or cytologically) confirmed, non-metastatic diagnosis of squamous cell carcinoma of head and neck (scchn). * achievement of major pathological reaponse (mpr) after surgery with neoadjuvant immunotherapy combined chemotherapy. * adequate bone marrow, liver, and renal function: absolute neutrophil count ≥ 1.5 × 10\^9/l, hemoglobin ≥ 9.0g/dl, platelets ≥100000/μl; alt and ast \< 2.5× upper limit of normal (uln), total bilirubin ≤ 1.5×uln； creatinine clearance ≥ 60 ml/min； aptt≤ 1.5×uln. exclusion criteria: * participant has metastatic/unresectable scchn. * have an active autoimmune disease requiring systemic treatment or a documented history of clinically severe autoimmune disease. * with active hepatitis b or c, or known history of positive hiv test, or acquired immunodeficiency syndrome. * with interstitial pneumonitis, non-infectious pneumonitis, active pulmonary tuberculosis, or history of pulmonary tuberculosis infection that were not controlled by treatment. * with active infection requiring systemic therapy. * received any investigational drug within 4 weeks prior to the first dose, or concurrently enrolled in another clinical trial. * any other factors that are not suitable for inclusion in this study judged by investigators.
safety and efficacy of cdca in ctx chenodeoxycholic acid (cdca) in patients affected by cerebrotendinous xanthomatosis (ctx)

Conditions: Cerebrotendinous Xanthomatoses

Summary: retrospective study of ctx patients to investigate the safety and clinical efficacy of chenodeoxycholic acid


Eligibility criteria:
inclusion criteria: diagnosis of ctx received treatment with cdca age between 2 and 75 years having at least one cholestanol level and/or urinary bile alcohol level no more than 3 months prior to treatment with cdca and one cholestanol level and/or urinary bile alcohol level post-treatment within 2 years from the beginning of therapy with cdca exclusion criteria: -
pioglitazone in impaired glucose tolerance

Conditions: Glucose Metabolism Disorders

Summary: in patients with impaired glucose tolerance (igt), the researchers want to study the relative effects of pioglitazone, simvastatin, or the combination of both on: * intima media thickness (imt) as an easily assessed marker of atherosclerosis * heart rate variability (hrv) as a marker of autonomic neuropathy * flow-mediated vasodilatation (fmd) of the brachial artery as a marker of endothelial function * vascular and metabolic lab parameters

we want to study the relative effects of pioglitazone, simvastatin or the combination of both on intima media thickness (imt), heart rate variability (hrv), flow-mediated vasodilatation (fmd) of the brachial artery and vascular/metabolic lab parameters in patients with impaired glucose tolerance (igt). previous studies have shown a reduction in imt for both pioglitazone and simvastatin in type 2 diabetics. many patients with diabetes mellitus develop diabetic polyneuropathy which can be assessed by measuring hrv. it has been shown that pioglitazone has a positive effect on hrv in type 2 diabetics. questions remain on the relative efficacy of pioglitazone and simvastatin on the parameters mentioned above. also, there is only scarce data in patients with igt (as opposed to overt diabetes mellitus). there are no data on the relative effects of pioglitazone and simvastatin on flow-mediated vasodilatation (fmd) of the brachial artery as a surrogate marker for endothelial function.

Eligibility criteria:
inclusion criteria: * impaired glucose tolerance * age 40 to 75 years exclusion criteria: * diabetes mellitus type 1 or 2 * hypersensitivity to study medication * malignant tumor * alcohol or drug abuse * overt heart failure * severe hepatic, renal, neurological, psychiatric, or hematological disease * prior treatment with glitazones or statins * established indication for statin treatment (e.g. coronary artery disease \[cad\])

Keywords: impaired glucose tolerance
coronary artery aneurysm registry

Conditions: Coronary Artery Aneurysm

Summary: international registry gathering patients with angiographically confirmed coronary aneurysm.

introduction and rationale: coronary artery aneurysm is defined as coronary dilatation which exceeds the diameter of normal adjacent segments or the diameter of the patient's largest coronary vessel by 1.5 times. described by bourgon, it is an uncommon disease which has been diagnosed with increasing frequency since the advent of coronary angiography. the incidence varies from 1.5% to 5% with male dominance and a predilection for the right coronary artery. although several causes have been reported, atherosclerosis accounts for 50% of coronary aneurysms in adults. reported complications include thrombosis and distal embolization, rupture and vasospasm, causing ischemia, heart failure or arrhythmias. the natural history and prognosis remains obscure, since definitive data are scarce. controversies persist regarding the use of medical management (antithrombotic) or interventional/surgical procedures. objectives. taking into account the classical coronary aneurysm definition, the investigators propose: * anatomic objectives. * to characterize coronary aneurysms frequency over all cause invasive coronary angiography. * to describe anatomy, location and aneurysms features. * to assess intracoronary imaging data if available. * to describe the natural history, when evolutive chats were available * clinical objectives. * cause for the diagnostic catheterization and aneurysms symptoms, if present. * patient´s clinical features. * long-term outcomes. * therapeutic objectives. * to assess management strategies, conservative, interventional or surgical and its short and long term results. * outcomes regarding management. design: * retrospective recruitment, prospective follow-up registry. * multicentric/international. * anonymized. * electronic database. centralized analysis (core) at hospital clínico san carlos. * recruitment: 1/january/2002-1/december/2015.

Eligibility criteria:
inclusion criteria (angiographic diagnosis): * coronary aneurysm: focal coronary dilatation which exceeds the diameter of normal adjacent segments or the diameter of the patient's largest coronary vessel by 1.5 times. exclusion criteria: * patient ´s refusal to participate.

Keywords: coronary artery aneurysm prognosis outcomes management incidence heart failure acute coronary syndrome death